Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities

Umme Ruman,1 Sharida Fakurazi,2,3 Mas Jaffri Masarudin,1,2,4 Mohd Zobir Hussein1 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 2Laboratory of Vaccine and Immunotherapeutics, Instit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ruman U, Fakurazi S, Masarudin MJ, Hussein MZ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	nanocarrier therapeutics theranostics drug delivery systems liver cancer nanodrug modalities Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/f2eff56a63f54067bbba38e4ef55e4e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f2eff56a63f54067bbba38e4ef55e4e2
record_format	dspace
spelling	oai:doaj.org-article:f2eff56a63f54067bbba38e4ef55e4e22021-12-02T09:33:12ZNanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities1178-2013https://doaj.org/article/f2eff56a63f54067bbba38e4ef55e4e22020-03-01T00:00:00Zhttps://www.dovepress.com/nanocarrier-based-therapeutics-and-theranostics-drug-delivery-systems--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Umme Ruman,1 Sharida Fakurazi,2,3 Mas Jaffri Masarudin,1,2,4 Mohd Zobir Hussein1 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 2Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience Universiti, Putra 43400, Malaysia; 3Department of Human Anatomy, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 4Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia, Serdang, Selangor 43400, MalaysiaCorrespondence: Mohd Zobir Hussein Email mzobir@upm.edu.myAbstract: The development of therapeutics and theranostic nanodrug delivery systems have posed a challenging task for the current researchers due to the requirement of having various nanocarriers and active agents for better therapy, imaging, and controlled release of drugs efficiently in one platform. The conventional liver cancer chemotherapy has many negative effects such as multiple drug resistance (MDR), high clearance rate, severe side effects, unwanted drug distribution to the specific site of liver cancer and low concentration of drug that finally reaches liver cancer cells. Therefore, it is necessary to develop novel strategies and novel nanocarriers that will carry the drug molecules specific to the affected cancerous hepatocytes in an adequate amount and duration within the therapeutic window. Therapeutics and theranostic systems have advantages over conventional chemotherapy due to the high efficacy of drug loading or drug encapsulation efficiency, high cellular uptake, high drug release, and minimum side effects. These nanocarriers possess high drug accumulation in the tumor area while minimizing toxic effects on healthy tissues. This review focuses on the current research on nanocarrier-based therapeutics and theranostic drug delivery systems excluding the negative consequences of nanotechnology in the field of drug delivery systems. However, clinical developments of theranostics nanocarriers for liver cancer are considered outside of the scope of this article. This review discusses only the recent developments of nanocarrier-based drug delivery systems for liver cancer therapy and diagnosis. The negative consequences of individual nanocarrier in the drug delivery system will also not be covered in this review.Keywords: nanocarrier, therapeutics, theranostics, drug delivery systems, liver cancer, nanodrug, modalitiesRuman UFakurazi SMasarudin MJHussein MZDove Medical Pressarticlenanocarriertherapeuticstheranosticsdrug delivery systemsliver cancernanodrugmodalitiesMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 1437-1456 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	nanocarrier therapeutics theranostics drug delivery systems liver cancer nanodrug modalities Medicine (General) R5-920
spellingShingle	nanocarrier therapeutics theranostics drug delivery systems liver cancer nanodrug modalities Medicine (General) R5-920 Ruman U Fakurazi S Masarudin MJ Hussein MZ Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
description	Umme Ruman,1 Sharida Fakurazi,2,3 Mas Jaffri Masarudin,1,2,4 Mohd Zobir Hussein1 1Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 2Laboratory of Vaccine and Immunotherapeutics, Institute of Bioscience Universiti, Putra 43400, Malaysia; 3Department of Human Anatomy, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia, Serdang, Selangor 43400, Malaysia; 4Faculty of Biotechnology and Biomolecular Science, Universiti Putra Malaysia, Serdang, Selangor 43400, MalaysiaCorrespondence: Mohd Zobir Hussein Email mzobir@upm.edu.myAbstract: The development of therapeutics and theranostic nanodrug delivery systems have posed a challenging task for the current researchers due to the requirement of having various nanocarriers and active agents for better therapy, imaging, and controlled release of drugs efficiently in one platform. The conventional liver cancer chemotherapy has many negative effects such as multiple drug resistance (MDR), high clearance rate, severe side effects, unwanted drug distribution to the specific site of liver cancer and low concentration of drug that finally reaches liver cancer cells. Therefore, it is necessary to develop novel strategies and novel nanocarriers that will carry the drug molecules specific to the affected cancerous hepatocytes in an adequate amount and duration within the therapeutic window. Therapeutics and theranostic systems have advantages over conventional chemotherapy due to the high efficacy of drug loading or drug encapsulation efficiency, high cellular uptake, high drug release, and minimum side effects. These nanocarriers possess high drug accumulation in the tumor area while minimizing toxic effects on healthy tissues. This review focuses on the current research on nanocarrier-based therapeutics and theranostic drug delivery systems excluding the negative consequences of nanotechnology in the field of drug delivery systems. However, clinical developments of theranostics nanocarriers for liver cancer are considered outside of the scope of this article. This review discusses only the recent developments of nanocarrier-based drug delivery systems for liver cancer therapy and diagnosis. The negative consequences of individual nanocarrier in the drug delivery system will also not be covered in this review.Keywords: nanocarrier, therapeutics, theranostics, drug delivery systems, liver cancer, nanodrug, modalities
format	article
author	Ruman U Fakurazi S Masarudin MJ Hussein MZ
author_facet	Ruman U Fakurazi S Masarudin MJ Hussein MZ
author_sort	Ruman U
title	Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_short	Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_full	Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_fullStr	Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_full_unstemmed	Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities
title_sort	nanocarrier-based therapeutics and theranostics drug delivery systems for next generation of liver cancer nanodrug modalities
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/f2eff56a63f54067bbba38e4ef55e4e2
work_keys_str_mv	AT rumanu nanocarrierbasedtherapeuticsandtheranosticsdrugdeliverysystemsfornextgenerationoflivercancernanodrugmodalities AT fakurazis nanocarrierbasedtherapeuticsandtheranosticsdrugdeliverysystemsfornextgenerationoflivercancernanodrugmodalities AT masarudinmj nanocarrierbasedtherapeuticsandtheranosticsdrugdeliverysystemsfornextgenerationoflivercancernanodrugmodalities AT husseinmz nanocarrierbasedtherapeuticsandtheranosticsdrugdeliverysystemsfornextgenerationoflivercancernanodrugmodalities
_version_	1718398098551603200

Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities

Ejemplares similares